News Archives - Page 399 of 808

WednesdayFeb 16, 2022 11:37 am

Focused on Pillars of Success for 2022, Friendable Inc. (FDBL) Disrupts Traditional Music Industry with “Anti-Label” Opportunities

Friendable recorded a 14,000% YOY increase in revenue (more than $20,000 in January 2022) and more than 8,000% YOY growth of its Fan Pass Live artist database, topping 105,000 artists Fan Pass Live platform offers the only all-inclusive option for independent artists, from live performances and merchandise creation (and sales) to music recording and distribution services The global music distribution services market was valued at $911.87 million in 2021 and is expected to reach $1.68 trillion by 2030 After closing out a successful 2021, the mobile technology and marketing company Friendable (OTC: FDBL), rang in the new year with an…

WednesdayFeb 16, 2022 11:13 am

Following Successful Sildenafil Animal Study, Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Plans for More Studies in 2022

Lexaria’s animal study could be the first step to developing faster and better acting sildenafil oral formulations The most prominent study for Lexaria in 2022 is HYPER-H21-4, investigating patented DehydraTECH(TM)-CBD for hypertension and heart disease Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, recently announced positive findings in an animal study that evaluated DehydraTECH(TM) processing of the phosphodiesterase inhibitor (PDE5 inhibitor) sildenafil as potential use for erectile dysfunction management. A clear trend emerged during the course of the study – a faster and higher overall delivery of sildenafil into the bloodstream (https://ibn.fm/oU4wW). During the animal study, it…

TuesdayFeb 15, 2022 9:30 am

Identified Psilocybin and MDMA Supplier, New Addition Strengthens Mydecine Innovations Group Inc.’s (NEO: MYCO) (OTC: MYCOF) Board Experience

Biotechnology company Mydecine Innovations Group is devoted to advancing the use of psychedelics for the treatment of mental illnesses and addiction Mydecine has necessary license to provide psilocybin and MDMA under Canada’s SAP program, which allows medical providers to request otherwise unavailable drug substances for the treatment of patients who have not seen success with available treatment options The license allows Mydecine to provide psilocybin and MDMA (Ecstasy) through its licensed Alberta facility and collaboration with non-profit drug development institute Applied Pharmaceutical Innovation The company has named pharmaceutical scientist and entrepreneur Dr. Victoria Hale to its Board of Directors, strengthening…

TuesdayFeb 15, 2022 9:15 am

Delic Holdings Corp. (CSE: DELC) (OTCQB: DELCF) Pushing the Conversation on Psychedelics and Access to Psychedelic Treatments for Persons Living with Mental Health Conditions

Delic seeks to bring mental health treatment closer to the people through an aggressive expansion plan In a study conducted by The Harris Poll on behalf of the company, it was noted that 65% of Americans dealing with mental health conditions believe that psychedelic medicine should be made available Studies such as these are helping Delic drive the conversation on psychedelics forward The company seeks to take this conversation further with its participation at this year’s Emerald Conference Over 51.5 million people have experienced a mental health condition in the United States alone, with the figures rising owing to the…

TuesdayFeb 15, 2022 9:00 am

Building Value for Companies and Investors: SRAX Inc. (NASDAQ: SRAX) Buys Back Stock, Pays Dividend

SRAX has published a replay of its recent 2022 Sequire Metals & Mining Conference, including keynotes, and presentations from 70+ premier companies Per the $10 million share repurchase plan announced in Q3 2021, SRAX repurchased approximately $800,000 worth of stock during Q4 The company also made its first dividend payment through the delivery of preferred stock to shareholders Most companies use technology to build value for themselves. SRAX (NASDAQ: SRAX) has taken it to a different level, using its technology to build corporate value by showcasing the opportunities in other companies. The Los Angeles-based company operates a portfolio of investor…

MondayFeb 14, 2022 10:15 am

LQwD FinTech Corp. (TSX.V: LQWD) (OTCQB: LQWDF) Releases International Nodes; Bitcoin Payment Ecosystem Market Expected to Reach US$880 Million by 2026

LQwD currently has three public nodes on the Lightning Network – US-West, Singapore, and Frankfurt LQwD’s first launched node, US-West has already experienced positive growth The company plans to release more international nodes in the future, facilitating its goal of being a prominent payment processor worldwide LQwD FinTech (TSX.V: LQWD) (OTCQB: LQWDF), a fintech company focused on creating enterprise-grade infrastructure to drive bitcoin adoption and the development of payment platform-as-a-service (“PaaS”) for the Bitcoin Lightning Network, has announced that it has deployed additional routing nodes in Germany and Singapore. The establishment of these nodes into these international financial hubs translates…

MondayFeb 14, 2022 10:00 am

Microdose Psychedelics Molecular Masterclass: LSD Conference Set to Explore The Potential Of LSD

Biotech experts, top LSD researchers, science specialists, influencers, and medical professionals are invited to attend the virtual LSD Conference being held on February 17, 2022. The agenda of the conference will include discussions, keynotes, and insights from world-class speakers focused on the research regarding therapeutic benefits and potential of LSD. The conference is organized by Microdose, a premier organization engaged in creating, offering and distributing the most compelling content on the finance, industry news, science, and the latest breakthroughs and events of the psychedelic industry. This is the biggest platform offering exposure to professionals, companies, and individuals about the events…

MondayFeb 14, 2022 9:45 am

Flora Growth Corp. (NASDAQ: FLGC) Seeks EUA to Test Cannabis Product Against COVID Virus, Building on Early Study Results as it Names New Chief Strategy Officer

Recent research efforts have targeted the potential of cannabis compounds to combat COVID-19 infection as the worldwide pandemic presses forward into its third year Perhaps most notable among the early-stage research efforts is a study by Oregon State University that found high doses of two specific cannabinoids bound to spike proteins such as COVID’S SARS-CoV-2 and inhibited their potential for infection Cannabis cultivator and brand builder Flora Growth Corp. has filed a provisional patent application for a cannabinoid-based formula that it is simultaneously seeking approval from Colombia’s food and drug regulatory authority for a study and potential clinical trial in…

MondayFeb 14, 2022 9:30 am

Nemaura Medical Inc.’s (NASDAQ: NMRD) CEO Dr. Faz Chowdhury Addresses Growing CGM Demand at H.C. Wainwright BioConnect Conference

NMRD CEO Dr. Faz Chowdhury presented at H.C. Wainwright BioConnect Conference held January 10-13, 2022 Presentation revealed growing need for CGM devices, diabetes market estimated at $150 billion NMRD's sugarBEAT(R) devices measure glucose at the skin surface, non-invasive, easy to use NMRD recently commenced product shipments in lieu of an order for 5,000 CGM devices and 200,000 sensors to UK licensing partner MySugarWatch Limited NMRD recently announced launch of Miboko metabolic health program targeted at global employers and insurers Dr. Faz Chowdhury, CEO of Nemaura Medical (NASDAQ: NMRD), recently presented at the H.C. Wainwright BioConnect Conference on January 10-13, 2022,…

MondayFeb 14, 2022 9:15 am

Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Receives IRB Approval for Kernel Flow Feasibility Study

Institution Review Board gives green light to study designed around Kernel’s quantitative neuroimaging technology Kernel Flow device provides ability to measure longitudinal brain activity before, during and after a psychedelic experience CYBN CEO says results from study will further support company’s mission to develop psychedelics into therapeutics Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has received approval to move forward on a key feasibility study designed to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics (https://ibn.fm/f0HXk). The approval, granted by the Institution Review Board (“IRB”), gives a green light to a Cybin-sponsored study…

Site Search

Company Search

Category: News